Sanara MedTech (SMTI)
(Delayed Data from NSDQ)
$34.68 USD
+1.17 (3.49%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $34.48 -0.20 (-0.58%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$34.68 USD
+1.17 (3.49%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $34.48 -0.20 (-0.58%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Zacks News
Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece
by Zacks Equity Research
SMTI, along with InfuSystem, inked a U.S. distribution agreement with ChemoMouthpiece. Under the agreement, ChemoMouthpiece's oral cryotherapy device will be distributed in cancer centers.
Down -14.23% in 4 Weeks, Here's Why Sanara MedTech Inc. (SMTI) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Sanara MedTech Inc. (SMTI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
What Makes Sanara MedTech Inc. (SMTI) a Good Fit for 'Trend Investing'
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Sanara MedTech Inc. (SMTI) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.